Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 51Central Nervous System Neoplasms 43Medulloblastoma 22Brain Neoplasms 20Astrocytoma 15Oligodendroglioma 14Rhabdoid Tumor 7Choroid Plexus Neoplasms 7Neoplasms 6Glioma 6Optic Nerve Glioma 5Ganglioneuroblastoma 5Spinal Cord Neoplasms 4Sarcoma 4Neuroectodermal Tumors, Primitive 4Glioblastoma 4Sarcoma, Ewing 3Rhabdomyosarcoma 3Recurrence 3Lymphoma 3Gliosarcoma 3Ependymoma 3Wilms Tumor 2Pinealoma 2Neurofibromatosis 1 2Familial ependymoma 2Untreated Childhood Medulloblastoma 1Retinoblastoma 1Pyloric Stenosis, Hypertrophic 1Ototoxicity 1

Interventions

trametinib 2dabrafenib 2mirdametinib 1gallium Ga 68 dotatate 1Vincristine 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ga(III)-DOTATOC 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ganglioneuroma × Vincristine × CNS × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡